Urinary microenvironment-degradable nanocapsules for traceable therapy of diabetic nephropathy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Diabetic nephropathy (DN) is a major cause of kidney failure.
• Current DN treatments face challenges like poor drug retention in kidneys.

Purpose of the Study:

• To develop a novel nanocapsule (MNP-THA@MnCaP) for targeted diabetic nephropathy (DN) therapy.
• To create a theranostic platform for simultaneous treatment and imaging of DN.

Main Methods:

• Designed urine-microenvironment responsive nanocapsules (MNP-THA@MnCaP) with a MnCaP nanoshell, melanin nanoparticles (MNP), and thalidomide (THA).
• Evaluated in vitro effects on renal tubular cells and in vivo efficacy in DN models.
• Utilized T1-weighted MRI and photoacoustic imaging for treatment tracking.

Main Results:

• MNP-THA@MnCaP demonstrated preferential kidney accumulation and controlled drug release in acidic urine.
• The formulation reduced oxidative stress, inflammation, fibrosis, and apoptosis in DN kidneys.
• Enabled real-time monitoring of DN treatment via MRI and photoacoustic imaging.

Conclusions:

• MNP-THA@MnCaP is a promising, biocompatible theranostic platform for diabetic nephropathy.
• The nanocapsule offers targeted drug delivery and imaging capabilities for improved DN management.